Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Therapy | 3 | 2016 | 71 | 1.240 |
Why?
|
| Periodicals as Topic | 2 | 2016 | 158 | 0.820 |
Why?
|
| Antidepressive Agents | 4 | 2006 | 216 | 0.730 |
Why?
|
| Drug Interactions | 6 | 2006 | 289 | 0.630 |
Why?
|
| Science | 1 | 2015 | 15 | 0.520 |
Why?
|
| Epidemics | 1 | 2015 | 12 | 0.500 |
Why?
|
| Analgesics, Opioid | 2 | 2015 | 498 | 0.460 |
Why?
|
| Cyclohexanols | 2 | 2004 | 12 | 0.450 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 135 | 0.450 |
Why?
|
| Triazoles | 2 | 2004 | 43 | 0.430 |
Why?
|
| Depressive Disorder | 3 | 2002 | 621 | 0.390 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2011 | 34 | 0.380 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2011 | 154 | 0.340 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 148 | 0.340 |
Why?
|
| Women's Health | 1 | 2016 | 148 | 0.260 |
Why?
|
| Fetus | 2 | 2011 | 157 | 0.260 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2006 | 5 | 0.250 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2002 | 54 | 0.250 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2004 | 12 | 0.230 |
Why?
|
| Fluoxetine | 1 | 2004 | 40 | 0.230 |
Why?
|
| Sertraline | 1 | 2004 | 62 | 0.230 |
Why?
|
| Decision Making | 1 | 2016 | 410 | 0.220 |
Why?
|
| Antimanic Agents | 1 | 2003 | 21 | 0.220 |
Why?
|
| Paroxetine | 1 | 2003 | 28 | 0.210 |
Why?
|
| Nausea | 1 | 2003 | 47 | 0.210 |
Why?
|
| Risperidone | 1 | 2003 | 48 | 0.210 |
Why?
|
| Bupropion | 1 | 2003 | 63 | 0.210 |
Why?
|
| Valproic Acid | 1 | 2003 | 93 | 0.210 |
Why?
|
| Half-Life | 4 | 2004 | 96 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 1 | 2003 | 102 | 0.200 |
Why?
|
| Substance P | 1 | 2001 | 39 | 0.200 |
Why?
|
| Humans | 17 | 2016 | 68618 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2003 | 223 | 0.190 |
Why?
|
| Neuropeptides | 1 | 2001 | 106 | 0.180 |
Why?
|
| Antipsychotic Agents | 1 | 2003 | 247 | 0.180 |
Why?
|
| Pregnancy, Animal | 1 | 1999 | 27 | 0.170 |
Why?
|
| Morphine | 1 | 1999 | 76 | 0.170 |
Why?
|
| Methylphenidate | 1 | 2000 | 97 | 0.170 |
Why?
|
| Protein Binding | 1 | 2002 | 1027 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2000 | 221 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2003 | 659 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2004 | 238 | 0.140 |
Why?
|
| Pharmacy | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 2 | 2006 | 2 | 0.120 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2004 | 42 | 0.110 |
Why?
|
| Delayed-Action Preparations | 2 | 2004 | 120 | 0.110 |
Why?
|
| Publishing | 1 | 2014 | 89 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2015 | 622 | 0.100 |
Why?
|
| Piperazines | 2 | 2004 | 206 | 0.100 |
Why?
|
| Animals | 5 | 2011 | 20881 | 0.090 |
Why?
|
| Pregnancy | 2 | 2011 | 2334 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 567 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 659 | 0.090 |
Why?
|
| Receptors, Serotonin | 2 | 2002 | 74 | 0.090 |
Why?
|
| Sleep | 2 | 2002 | 263 | 0.070 |
Why?
|
| Carbon Radioisotopes | 1 | 2004 | 34 | 0.060 |
Why?
|
| Alprazolam | 1 | 2004 | 35 | 0.060 |
Why?
|
| Molecular Probes | 1 | 2004 | 27 | 0.060 |
Why?
|
| Erythromycin | 1 | 2004 | 13 | 0.060 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2004 | 22 | 0.060 |
Why?
|
| Breath Tests | 1 | 2004 | 23 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2004 | 62 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 260 | 0.060 |
Why?
|
| Female | 4 | 2016 | 38074 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2004 | 411 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2003 | 80 | 0.050 |
Why?
|
| Sex Factors | 1 | 2016 | 1266 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2003 | 107 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 2002 | 31 | 0.050 |
Why?
|
| Morpholines | 1 | 2001 | 79 | 0.050 |
Why?
|
| Quinidine | 1 | 2000 | 15 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2000 | 120 | 0.040 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2000 | 20 | 0.040 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2000 | 30 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2001 | 236 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 89 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1999 | 57 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 1999 | 282 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2000 | 284 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 301 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2002 | 426 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1999 | 381 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 931 | 0.040 |
Why?
|
| Absorption | 1 | 1998 | 49 | 0.040 |
Why?
|
| Pain | 1 | 2001 | 472 | 0.040 |
Why?
|
| Solubility | 1 | 1998 | 134 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 1998 | 169 | 0.040 |
Why?
|
| Phenotype | 1 | 2000 | 947 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 1998 | 420 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 1998 | 213 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 848 | 0.030 |
Why?
|
| Male | 3 | 2004 | 37321 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2001 | 824 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 2083 | 0.030 |
Why?
|
| Depression | 1 | 2001 | 943 | 0.030 |
Why?
|
| Middle Aged | 2 | 2004 | 21147 | 0.030 |
Why?
|
| Adult | 2 | 2004 | 21403 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 1745 | 0.030 |
Why?
|
| Quality of Life | 1 | 2000 | 1515 | 0.020 |
Why?
|
| Rats | 1 | 1999 | 5300 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2000 | 7029 | 0.020 |
Why?
|
| Adolescent | 1 | 2000 | 8912 | 0.020 |
Why?
|
| Aged | 1 | 2003 | 14862 | 0.020 |
Why?
|